Lancet Gastroenterol Hepatol: The CAP 02 study by Professor Wang Feng from the First Affiliated Hospital of Zhengda University shows that camrelizumab combined with apatinib is effective in second-line treatment of advanced esophageal squamous cell carcinoma

Recently, Lancet Gastroenterol Hepatol published the full text of the CAP 02 (NCT03736863) study online.

Recently, Lancet Gastroenterol Hepatol published the full text of the CAP 02 (NCT03736863) study online.

The CAP 02 study is a single-arm, open-label, multi-center, phase II clinical study, led by the First Affiliated Hospital of Zhengzhou University, with the participation of 8 hospitals in Henan Province

The CAP 02 study is a single-arm, open-label, multi-center, phase II clinical study, led by the First Affiliated Hospital of Zhengzhou University, with the participation of 8 hospitals in Henan Province

Between December 5, 2019, and February 10, 2021, a total of 52 patients were enrolled, of which 94% were patients with distant metastases

Efficacy assessment

Of the total 52 patients, 26 had disease progression or death at data cutoff

Of the total 52 patients, 26 had disease progression or death at data cutoff

PFS and OS

In a post hoc subgroup analysis, the ORR was 44% in patients with PD-L1 CPS ≥ 1 and 46% in patients with PD-L1 CPS < 1

In a post hoc subgroup analysis, the ORR was 44% in patients with PD-L1 CPS ≥ 1 and 46% in patients with PD-L1 CPS < 1

In terms of safety, the incidence of treatment-related adverse events of grade ≥ 3 was 44%, and the common adverse events of grade ≥ 3 were increased aspartate aminotransferase (10/52, 19%), increased γ-glutamyltransferase.

Adverse reactions

In conclusion, the study showed that camrelizumab combined with apatinib in the second-line treatment of advanced esophageal squamous cell carcinoma has a significant curative effect and is safe and controllable

In conclusion, the study showed that camrelizumab combined with apatinib in the second-line treatment of advanced esophageal squamous cell carcinoma has a significant curative effect and is safe and controllable

Original source:

Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S , Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F.

Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S , Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F.
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol.
2022 Jan 6:S2468-1253(21)00378-2.
doi: 10.
1016/S2468-1253(21)00378-2.
Epub ahead of print.
PMID: 34998471.


Leave a message here